A widely available drug for urinary tract infections has never been formally approved by the US government. It’s not the only ...

Recently approved medications for resistant hypertension, uncomplicated UTIs and menopausal hot flashes show potential as ...

Prevalence of UTIs in Indian population is estimated to be around 33%. Men have less than 15% chance of developing this ...

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or ...

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs ... for the treatment of cUTIs in adults, including severe kidney ...

Treatment with retifanlimab plus carboplatin ... musculoskeletal pain, diarrhea, non-urinary tract infections, perineal pain, hemorrhage, urinary tract infection, rash, nausea, decreased appetite ...

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of ...

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.